Will BCI Deal Change Butterfly Network Stock Narrative

• Butterfly Network recently reported a multi-year R&D agreement with Bridge Neurotech through Butterfly Embedded, covering Ultrasound-on-Chip licensing, milestone payments, and committed hardware purchases for non-surgical brain computer interface research.
• The first commercial launch of a Butterfly Embedded partner product and the appointment of semiconductor veteran Mike Noonen to the board both indicate that Butterfly Network is placing greater emphasis on its chip platform as a core business driver.
• We will now assess how Butterfly Network's new brain-computer interface focused R&D agreement might reshape the existing investment narrative for the business.

Capitalize on Butterfly Network's push into brain computer interfaces and chip platforms by scanning a hand-picked group of 34 healthcare AI stocks that could be building similar long-term storylines.

Butterfly Network Investment Narrative Recap

To own Butterfly Network, you need to believe its handheld ultrasound and embedded chip platforms can turn strong forecast top line expansion into a more durable, software heavy model over time. In the short term, the main swing factor still looks like execution on large enterprise, education and HomeCare programs, because these contracts influence both recurring revenue and the path toward better margins.

The biggest near term risk stays the same. Heavy R&D and semiconductor spend sit against a business that remains loss making, with a share price that has been volatile and a P/S multiple well above peers. The Bridge Neurotech deal adds some revenue visibility but does not materially change that profitability and funding challenge right now.

The Bridge Neurotech R&D agreement is the most relevant update. It directly leans on Butterfly Network’s Ultrasound on Chip platform and Butterfly Embedded program, and it comes with licensing fees, milestones and committed hardware purchases. That structure gives a clearer line of sight on how the chip business could translate technical work into contracted income instead of purely aspirational roadmaps.

For catalysts, this matters in two ways. First, it validates the embedded model alongside Mendaera’s recent commercial launch. Second, it helps support ongoing R&D while analysts still expect operating losses over the next few years. Execution risk remains important to watch. The key questions now are contract delivery, follow on deals in adjacent areas like BCIs, and whether that momentum feeds into the upcoming earnings updates.

Butterfly Network’s current analyst framework points to revenues of US$258.1 million and earnings of US$32.5 million by 2029, based on forecast top line growth of 32.0% a year and an earnings swing of roughly US$107.3 million from a loss of US$74.8 million today to positive territory on those future estimates.

Uncover why Butterfly Network's fair value indicates a 38% potential upside to its current price, which could narrow quickly.

Exploring Other Perspectives

One alternate angle to watch is churn in Butterfly Network’s software subscriptions. The most cautious analysts were already baking in slower conversion to SaaS, with revenue forecasts of about US$217.2 million and earnings of US$27.3 million by 2029. Those estimates came before this BCI news, so your view might shift as fresh scenarios emerge.

Explore 4 other Butterfly Network fair value estimates, including one that suggests as much as 78% downside from the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Butterfly Network research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• See our latest analysis for Butterfly Network. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Butterfly Network's overall financial health at a glance.

Looking for more Butterfly Network style investment ideas?

If the Butterfly Network story has you thinking about where else similar themes might play out, the Simply Wall St Screener can help you cast a wider net without losing focus on quality and fit.

• If capital preservation matters most to you, start with companies that have steadier profiles by reviewing a 31 resilient stocks with low risk scores that may better match your tolerance for drawdowns.
• If resilience on the balance sheet is your priority, filter for stronger funding positions and cleaner leverage using a curated list of solid balance sheet and fundamentals (25 results).
• If you are hunting for underappreciated opportunities, widen the search to a broader 20 high quality undiscovered gems that might not yet be widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com